Subscribe
Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.
Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial Primer
Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action
Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials
Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP
Neil M. Iyengar, MD; Swati Vishwanathan, MD
1 Session is Available!
3 Sessions are Available!
Sarah M. Tolaney, MD, MPH; Yelda Nouri, MD
Daniela A. Bota, MD, PhD; Maya Hrachova, DO
Geoffrey Ku, MD; Girish Kunapareddy, MD
2 Sessions are Available!
Jonathan Barratt, PhD, FRCP; Brendon L. Neuen, MBBS, PhD, MSc
Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD
Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD
Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA
Dilsher S. Dhoot, MD, FASRS
Deep Parikh, MD
Matthew Heeney, MD; Biree Andemariam, MD
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
James F. Howard Jr, MD, FAAN; Tuan Vu, MD